Novartis Vaccines and Diagnostics, 53100 Siena, Italy.
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3770-5. doi: 10.1073/pnas.0915162107. Epub 2010 Feb 3.
GNA2132 is a Neisseria meningitidis antigen of unknown function, discovered by reverse vaccinology, which has been shown to induce bactericidal antibodies in animal models. Here we show that this antigen induces protective immunity in humans and it is recognized by sera of patients after meningococcal disease. The protein binds heparin in vitro through an Arg-rich region and this property correlates with increased survival of the unencapsulated bacterium in human serum. Furthermore, two proteases, the meningococcal NalP and human lactoferrin, cleave the protein upstream and downstream from the Arg-rich region, respectively. We conclude that GNA2132 is an important protective antigen of N. meningitidis and we propose to rename it, Neisserial Heparin Binding Antigen (NHBA).
GNA2132 是一种脑膜炎奈瑟菌抗原,其功能未知,通过反向疫苗学发现,该抗原已被证明能在动物模型中诱导杀菌抗体。在这里,我们表明该抗原在人类中诱导保护性免疫,并且它被脑膜炎球菌病患者的血清所识别。该蛋白通过富含精氨酸的区域体外结合肝素,并且该特性与未包裹细菌在人血清中的存活增加相关。此外,两种蛋白酶,脑膜炎奈瑟菌 NalP 和人乳铁蛋白,分别在富含精氨酸的区域上下游切割该蛋白。我们得出结论,GNA2132 是脑膜炎奈瑟菌的一个重要保护性抗原,我们建议将其重新命名为,奈瑟氏肝素结合抗原(NHBA)。